Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial

Shahram Majidi; Jose I. Suarez; Adnan I. Qureshi

doi:10.1007/s12028-016-0341-z

Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial

Shahram Majidi, Jose I. Suarez, Adnan I. Qureshi

Neurology

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Acute hypertensive response is elevation of systolic blood pressure (SBP) in the first 24 h after symptom onset which is highly prevalent in patients with intracerebral hemorrhage (ICH). Observational studies suggested association between acute hypertensive response and hematoma expansion, peri-hematoma edema and death and disability, and possible reduction in these adverse outcomes with treatment of acute hypertensive response. Recent clinical trials have focused on determining the clinical efficacy of early intensive SBP reduction in ICH patients. The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-2) trial was the latest phase 3 randomized controlled multicenter clinical trial aimed to study the efficacy of early intensive reduction of SBP in ICH patients. In this review article, we summarize the results of recent clinical trials, treatment principles based on the latest guidelines, and the anticipated interpretation and incorporation of ATACH-2 trial results in clinical practice.

Original language	English (US)
Pages (from-to)	249-258
Number of pages	10
Journal	Neurocritical Care
Volume	27
Issue number	2
DOIs	https://doi.org/10.1007/s12028-016-0341-z
State	Published - Oct 1 2017

Keywords

Acute hypertensive response
Clinical trial
Death
Disability
Hematoma expansion
Intracerebral hemorrhage
Randomization
Systolic blood pressure

Publisher link

10.1007/s12028-016-0341-z

Find It

Find It at U of M Libraries

Cite this

@article{6fb0874331524724a45028dcc59e557b,

title = "Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial",

abstract = "Acute hypertensive response is elevation of systolic blood pressure (SBP) in the first 24 h after symptom onset which is highly prevalent in patients with intracerebral hemorrhage (ICH). Observational studies suggested association between acute hypertensive response and hematoma expansion, peri-hematoma edema and death and disability, and possible reduction in these adverse outcomes with treatment of acute hypertensive response. Recent clinical trials have focused on determining the clinical efficacy of early intensive SBP reduction in ICH patients. The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-2) trial was the latest phase 3 randomized controlled multicenter clinical trial aimed to study the efficacy of early intensive reduction of SBP in ICH patients. In this review article, we summarize the results of recent clinical trials, treatment principles based on the latest guidelines, and the anticipated interpretation and incorporation of ATACH-2 trial results in clinical practice.",

keywords = "Acute hypertensive response, Clinical trial, Death, Disability, Hematoma expansion, Intracerebral hemorrhage, Randomization, Systolic blood pressure",

author = "Shahram Majidi and Suarez, {Jose I.} and Qureshi, {Adnan I.}",

year = "2017",

month = oct,

day = "1",

doi = "10.1007/s12028-016-0341-z",

language = "English (US)",

volume = "27",

pages = "249--258",

journal = "Neurocritical Care",

issn = "1541-6933",

publisher = "Humana Press",

number = "2",

}

TY - JOUR

T1 - Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial

AU - Majidi, Shahram

AU - Suarez, Jose I.

AU - Qureshi, Adnan I.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Acute hypertensive response is elevation of systolic blood pressure (SBP) in the first 24 h after symptom onset which is highly prevalent in patients with intracerebral hemorrhage (ICH). Observational studies suggested association between acute hypertensive response and hematoma expansion, peri-hematoma edema and death and disability, and possible reduction in these adverse outcomes with treatment of acute hypertensive response. Recent clinical trials have focused on determining the clinical efficacy of early intensive SBP reduction in ICH patients. The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-2) trial was the latest phase 3 randomized controlled multicenter clinical trial aimed to study the efficacy of early intensive reduction of SBP in ICH patients. In this review article, we summarize the results of recent clinical trials, treatment principles based on the latest guidelines, and the anticipated interpretation and incorporation of ATACH-2 trial results in clinical practice.

AB - Acute hypertensive response is elevation of systolic blood pressure (SBP) in the first 24 h after symptom onset which is highly prevalent in patients with intracerebral hemorrhage (ICH). Observational studies suggested association between acute hypertensive response and hematoma expansion, peri-hematoma edema and death and disability, and possible reduction in these adverse outcomes with treatment of acute hypertensive response. Recent clinical trials have focused on determining the clinical efficacy of early intensive SBP reduction in ICH patients. The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-2) trial was the latest phase 3 randomized controlled multicenter clinical trial aimed to study the efficacy of early intensive reduction of SBP in ICH patients. In this review article, we summarize the results of recent clinical trials, treatment principles based on the latest guidelines, and the anticipated interpretation and incorporation of ATACH-2 trial results in clinical practice.

KW - Acute hypertensive response

KW - Clinical trial

KW - Death

KW - Disability

KW - Hematoma expansion

KW - Intracerebral hemorrhage

KW - Randomization

KW - Systolic blood pressure

UR - http://www.scopus.com/inward/record.url?scp=85006921164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006921164&partnerID=8YFLogxK

U2 - 10.1007/s12028-016-0341-z

DO - 10.1007/s12028-016-0341-z

M3 - Review article

C2 - 28004328

AN - SCOPUS:85006921164

SN - 1541-6933

VL - 27

SP - 249

EP - 258

JO - Neurocritical Care

JF - Neurocritical Care

IS - 2

ER -

Management of Acute Hypertensive Response in Intracerebral Hemorrhage Patients After ATACH-2 Trial

Abstract

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this